SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TLSA

Tiziana Life Sciences Ltd (NASDAQ:TLSA)

GB · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.62-$0.06 (-8.14%)
 
Market cap
$79.5M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 20, 2018
Market Cap$79.45M-64.1%
Revenue (ttm)$0
Net Income-$25.19M-14.4%
EPS-$0.21+0.5%
Shares Out128.03M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume231,243
Open$0.68
Previous Close$0.68
Day's Range$0.61 - $0.68
52-Week Range$0.55 - $1.90
Beta0.46
AnalystsBuy
Price Targetn/a
Earnings Daten/a
-9.71% (1D)
No price history available.

About TLSA

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.

Address
14/15 Conduit Street, London, W1S 2XJ, GB
Market Cap
79 million
Employees
10
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$1.04M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating TLSA in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Distressed
From TLSA’s reported statements · Q2 2026 (trailing 12 months) · 3 of 5 pillars
1 Day
-8.14%
5 Days
+8.52%
1 Month
-37.94%
6 Months
-58.07%
1 Year
-64.13%

$TLSA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in TLSA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TLSA's directors and management

Net Shares Purchased by Insiders−2M−1M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TLSA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New TLSA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TLSA from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from TLSA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
63.41
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Positive clinical trial results and mechanism of action data for lead MS program support advancement toward partnerships and commercialization.

Recent Insider Activity

Buys
5
Sells
0
Buy Value
$1.04M
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.